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AbstrACt
Introduction Central nervous system (CNS) gliomas are 
the most common primary intra-axial brain tumours and 
pose variable treatment response according to their grade, 
therefore, precise staging is mandatory. Histopathological 
analysis of surgical tumour samples is still deemed as the 
state-of-the-art staging technique for gliomas due to the 
moderate specificity of the available non-invasive imaging 
modalities. A recently evolved analysis of the tissue water 
diffusion properties, known as diffusional kurtosis imaging 
(DKI), is a dimensionless metric, which quantifies water 
molecules’ degree of non-Gaussian diffusion, hence 
reflects tissue microenvironment’s complexity by means 
of non-invasive diffusion-weighted MRI acquisitions. The 
objective of this systematic review and meta-analysis 
is to explore the performance of DKI in the presurgical 
grading of gliomas, both regarding the differentiation 
between high-grade and low-grade gliomas as well as the 
discrimination between gliomas and other intra-axial brain 
tumours.
Methods and analysis We will search PubMed, Medline 
via Ovid, Embase and Scopus in July 2018 for research 
studies published between January 1990 and June 2018 
with no language restrictions, which have reported on the 
performance of DKI in diagnosing CNS gliomas. Robust 
inclusion/exclusion criteria will be applied for selection 
of eligible articles. Two authors will separately perform 
quality assessment according to the quality assessment of 
diagnostic accuracy studies-2 tool. Data will be extracted 
in a predesigned spreadsheet. A meta-analysis will be 
held using a random-effects model if substantial statistical 
heterogeneity is expected. The heterogeneity of studies will 
be evaluated, and sensitivity analyses will be conducted 
according to individual study quality.
Ethics and dissemination This work will be based on 
published studies; hence, it does not require institutional 
review board approval or ethics clearance. The results will 
be published in peer-reviewed journals.
PrOsPErO registration number CRD42018099192.
IntrOduCtIOn 
Gliomas are the most common primary 
intra-axial brain tumours. Precise and robust 
diagnosis and staging are crucial for imple-
menting successful management strategies 
and predicting their outcome. However, there 
is noticeable variation in individual tumour 
response even if they are attributed the same 
histological grade. This could be explained by 
the divergent proliferative patterns, cellular 
complexity and neovascularisation among 
these tumours.1 WHO 2007 classification used 
to classify brain gliomas into four subgroups 
depending on their histopathological features 
such as cellular atypia, mitotic activity and 
anaplasia.2 Meanwhile, efforts have been made 
in order to further stratify gliomas based on 
their molecular features aiming to better 
explain the tumours’ behaviour and deter-
mine better treatment strategies. The revised 
fourth edition of the updated WHO classifi-
cation of central nervous system tumours in 
2016 incorporates both molecular and histo-
pathological features of gliomas.3 As previously, 
histopathological examination after neurosur-
gical sampling is still considered as the state-of-
the-art staging method of gliomas; owing to the 
strengths and limitations of this study
 ► The findings of this review and meta-analysis will 
contribute to implementing diffusional kurtosis 
imaging  (DKI) in the routine MRI assessment and 
staging of intra-axial brain tumours and gliomas, 
respectively.
 ► The conducted meta-analysis will provide evidence 
on the diagnostic performance of the technique 
which will help to establish a universally accepted 
standardised DKI imaging protocol.
 ► The quality assessment of the studies will follow the 
modified quality assessment of diagnostic accuracy 
studies-2 tool offering an objective method for eval-
uating risk of bias in the studies.
 ► This study will strongly follow the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses of 
Diagnostic Test Accuracy Studies checklist.
 ► The limitation of this work will be any heterogene-
ity among the included studies in image acquisition 
techniques, postprocessing image analysis method-
ologies and variability in the extracted DKI metrics.
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moderate specificity of non-invasive imaging techniques.4 5 
On the other hand, there is a demand for reliable non-in-
vasive imaging methods, namely for patients who are unfit 
for surgery, to elucidate concerns regarding postbiopsy 
complications, or even to diagnose patients with suspected 
low-grade gliomas whose management can be regular 
follow-up.3 In the last few years, both diffusion-weighted 
imaging (DWI) and diffusion tensor imaging (DTI) have 
emerged as presurgical imaging tools and as tools for eval-
uating treatment response to chemotherapy and radio-
therapy regimens in patients with gliomas.6 However, DWI 
and DTI quantify water molecules’ mobility on the assump-
tion of unrestricted—but possibly hindered—random 
diffusion. Accordingly, the likelihood of certain proton 
diffusing from one location to another in a given time 
(known as the probability distribution function, PDF) is 
thought to be Gaussian related.7 However, the paramount 
differences inside the brain tissue cytoarchitecture due to 
cell membranes, organelles and discrete compartments 
will drift the diffusion of water molecules from the normal 
Gaussian distribution. Therefore, the real PDF will be more 
soared up in contrast to the Gaussian PDF. The widely 
used metric of diffusion attenuation in tumours, namely 
the apparent diffusion coefficient, is limited in detecting 
this deviation from the normal Gaussian behaviour. A 
novel diffusion model known as diffusional kurtosis 
imaging (DKI) is a dimensionless metric that has recently 
evolved to quantify water molecules’ degree of non-Gauss-
ianity.1 7 Thus, DKI can provide a more realistic biomarker 
that reflects the brain microenvironment’s complexity.8 It 
is simply considered a continuation of the DTI model and 
at least 2 non-zero diffusion gradient factors (b-values) in 
more than 15 non-linear diffusion directions are applied 
to acquire both the kurtosis metrics (radial kurtosis, axial 
kurtosis and mean kurtosis (Mk)) and the diffusion tensor 
metrics (mean diffusivity and fractional anisotropy simulta-
neously.1 It is therefore important to understand the diag-
nostic performance of DKI, both regarding its ability to 
stage the gliomas in subgroups and to differentiate gliomas 
from other intra-axial brain tumours.
Recent studies have shown promising results.8 9 In April 
2018, a systematic review and meta-analysis of the diag-
nostic accuracy of DKI for glioma grading revealed that 
the pooled area under the curve for Mk in differenti-
ating high-grade from low-grade gliomas was 0.94.10 This 
review included only 10 studies, whereas in the current 
work, we believe that more studies about DKI have been 
held in the interim. Moreover, we aim to include studies 
that compared DKI between gliomas and other intra-axial 
brain tumours.
ObjECtIvE
This review aims to investigate the diagnostic perfor-
mance of DKI in the grading of gliomas and the differ-
entiation between gliomas and other intra-axial brain 
tumours.
rEvIEw quEstIOns
How accurate is DKI in differentiating between high-
grade and low-grade gliomas and in differentiating brain 
gliomas from other intra-axial tumours?
MEthOds
This review protocol was developed according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses-Protocols (PRISMA) statement and guid-
ance from the Joanna Briggs Institute Reviewers’ Manual 
for the systematic review of studies of diagnostic test accu-
racy.11 12 The subsequent full systematic review will be 
prepared according to the PRISMA-Diagnostic Test Accu-
racy Studies checklist.13
Patient and public involvement
This work will be based on published studies; hence, there 
will not be patient or public involvement. The results will 
be published in peer-reviewed journals.
Inclusion and exclusion criteria
We will include all studies that have investigated DKI 
in tumours of glial cell origin, either primary or recur-
rent gliomas, in adult patients, using either WHO 2007 
or WHO 2016 classifications and compared the DKI 
features in gliomas with other non-glial tumours. Exclu-
sion criteria will comprise paediatric groups, non-orig-
inal research articles (reviews, commentaries, erratum, 
books, editorial and conference abstracts), animal 
studies, non-imaging studies, non-MRI studies, non-DKI 
Table 1 Search Syntax in PubMed and Medline
Database Search syntax
PubMed ("Glioma"[Mesh] OR "Brain Neoplasms"[Mesh] 
OR glioma[TW] OR gliomas[TW] OR (brain[TW] 
AND neoplasm*[TW])) AND ((diffusion[TW] 
AND kurtosis[TW]) OR (diffusional[tw] 
AND kurtosis[TW]) OR DKI[TW] OR “non-
Gaussian”[TW])




5. 1 or 2 or 3 or 4
6. exp Glioma/
7. exp Brain Neoplasms/
8. (glioma or gliomas or brain neoplasm*).
mp. [mp=title, abstract, original title, name 
of substance word, subject heading word, 
keyword heading word, protocol supplementary 
concept word, rare disease supplementary 
concept word, unique identifier, synonyms]
9. 6 or 7 or 8
10. 5 and 9 
 o
n




pen: first published as 10.1136/bmjopen-2018-025123 on 14 December 2018. Downloaded from 
3Abdalla G, et al. BMJ Open 2018;8:e025123. doi:10.1136/bmjopen-2018-025123
Open access
DWI-MRI studies, non-neoplastic conditions, non-glial 
tumours only, non-cerebral tumours and studies written 
in languages other than English, French or German.
search strategy for identification of studies
A systematic literature search will be developed in July 
2018 in four databases: PubMed, Medline via Ovid, Scopus 
and Embase using the keywords ‘glioma’ and ‘diffusional 
kurtosis’ by both medical subject heading and text words, 
without language restrictions. The suggested search 
syntax on PubMed and Medline is summarised in table 1 
and the flow chart is illustrated in figure 1.
study selection for inclusion in the review
Initially, studies identified by the literature search will 
be independently screened for primary eligibility by 
two authors, based on title and abstract. Full text of the 
primarily eligible studies will be independently assessed 
for final inclusion in the systematic review and meta-anal-
ysis by the same raters. Any disagreements will be resolved 
through discussions. Reasons for study exclusion will be 
stated clearly.
quAlIty AssEssMEnt
Eligible studies will be independently assessed according 
to the revised tool of quality assessment of diagnostic 
accuracy studies-2 tool14 by two coauthors. Any disagree-
ments will be resolved by consensus. The tool comprises 
four key domains which are: patient selection, index 
test, reference standard and patients’ flow in the study 
and timing of the reference standard and the index test. 
Under each domain, risk of bias will be assessed through 
answers to signalling questions given in the tool, taking 
into account the review questions. Regarding the patient 
selection domain, retrospective studies will be consid-
ered to have high risk of bias, meanwhile low risk will be 
attributed to prospective studies. Regarding the index 
test domain, whether the neuroradiologist was blinded to 
the pathology during the image processing and region 
of interest drawing or not will determine the risk of bias; 
the neuroradiologists being blinded indicates low risk 
of bias. Histopathological results will serve as the refer-
ence standard. In the domain of flow and timing, unclear 
risk of bias will be ascertained if the interval between the 
Figure 1 Flow diagram for search strategy. CNS, central nervous system; DKI, diffusional kurtosis imaging.
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index test and the reference standard is not mentioned 
in the study. Additionally, unclearness will be considered 
also if any patient was excluded from the analysis without 
relevant reasons. Concerns regarding applicability will be 
assessed in the first three domains only.
dAtA ExtrACtIOn And MAnAgEMEnt
Data extraction will be performed by two coauthors in 
a predesigned standardised sheet. Extracted data will 
include the following: first author name, publication year, 
type of study, details about the patient population, data 
acquisition techniques, image processing, postprocessing 
software, reference standard and diagnostic test accuracy 
results (true-positive, false-positive, true-negative and 
false-negative values). Any missing data will be requested 
from the related study authors.
dAtA synthEsIs And AnAlysEs
We will construct 2×2 tables using reported number of 
true-positive, false-positive, false-negative and true-neg-
ative cases to calculate different indicators of diagnostic 
performance. A narrative synthesis will summarise the 
available evidence. Paired forest plots illustrating sensi-
tivity and specificity with their 95% CIs will be built 
using the Review Manager software. We will use a bivar-
iate random-effect model for data synthesis based on the 
assumption that studies are of sufficient heterogeneity in 
terms of study populations and study methodology. We 
will also report the number of true positives, false posi-
tives, true negatives and false negatives. A random-effect 
meta-analysis as well as aggregation of data using the hier-
archical summary receiver operator characteristics will be 
pursued.
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